Celebrating the new specialists in General Surgery at ๐ Padova University ๐
Congratulations ๐ on your achievement after 5 incredibile years to Francesco, Stela, Dario and Camilla!!!
โจโจโจ
Waiting 4 you all in Padova ๐๐๐
๐ธ Wirsung 2๏ธโฃ0๏ธโฃ2๏ธโฃ7๏ธโฃ Punkreas Revolution
The Revolution is finally here!
โฌ๏ธโฌ๏ธโฌ๏ธ
๐ด๐ด Mark your calendars!!! ๐๏ธ January 21-23 will put Padova in the spotlight โจ
๐ธ Wirsung 2027 ๐ค Punkreas Revolution!
๐ A stellar International faculty including the one and only @DeMadaria ๐ช๐ธ
๐ค and a full session on tele surgery of the pancreasโฆ
๐คณ Scan the code!
๐ธ๐ฌ What a week at #IHPBA2026 in Singapore!
Grateful for the opportunity to share our research and connect with the amazing international HPB community.
Great science, inspiring people, exciting collaborations, and unforgettable moments with my ๐ฎ๐น & ๐ณ๐ฑ families!
1/1 Let's wrap up this @IHPBA 2026 congress!
Some personal highlights:
โข Presenting a lecture about pancreatic leaks/pancreatitis in a very big room: scary, but very exciting
โ๏ธ Creativity meets surgery at the ECG Retreat
A fantastic Surgical Drawing Workshop, bringing together early career surgeons.
A special thank you to the wonderful instructors for sharing their expertise and to all the participants for their enthusiasm and engagement! ๐
๐ A new era in pancreatic cancer research is taking shape!
๐ช๐บ โฌ10M in EU Horizon Europe funding for @PALACROSeu 26 centers across 12 countries joining forces to improve treatment for LAPC
The future is changing. And weโre thrilled to help shape it! ๐ช
Pancreatic cancer in Italy ๐ฎ๐น in 2035
Check out our new paper ๐ in @UpdatesSurgery and help us taking urgent ๐จ action!
https://t.co/knygrCRpX4
๐ฎ๐น Pancreatic cancer in Italy: what will 2035 look like?
๐ >13% increase in deaths
๐ด Driven largely by population aging
โ ๏ธ But with a striking NorthโSouth divide in mortality trends.
๐Forecasting disease burden is healthcare planning๐
https://t.co/USL7OM29pm
๐ด๐ดDuring the past few days we had the enormous pleasure to host the first surgical residents led conference, dedicated to other residents and medicine students ๐ ResidentX!
๐ Together with guests ๐บ๐ธ like @cwolfga2 we warmly welcome the 32 new residents in general surgery!
๐จ If you do pancreas surgery you do FEAR chronic corticosteroid therapiesโฆ
๐ฎ๐น๐บ๐ธ๐ณ๐ฑ๐ฏ๐ต 2.5k patients matched per therapy
๐Chronic steroids led to โฌ๏ธ morbidity, mortality (10%!) and infections
๐ด Risk stratification should be balanced accordingly!
https://t.co/7JfjhP0Bq6
Personalised decision-making in hepatocellular carcinoma: conceptual evolution over two decades
โก๏ธhttps://t.co/6rARFJYJNt
Evidence-based medicine was conceived to integrate best available evidence, clinical expertise, and patient values, yet in many fields it has come to be equated with rigid guideline algorithms. This narrative, conceptual review draws selectively on landmark staging frameworks, guidelines, and methodological literature to trace two decades of decision-making in hepatocellular carcinoma across a sequence of schematic frames: stage-centred algorithms, recognition of differential treatment effects, multiparametric expert deliberation, and dynamic, time-dependent bidirectional strategies reinforced by immune checkpoint inhibitor combinations. The trajectory culminates in explicit acknowledgement of irreducible uncertainty, with the multiparametric therapeutic hierarchy positioned at the interface between baseline and treatment-conditioned prognosis and aligned with GRADE evidence-to-decision principles. The authors conclude that hepatocellular carcinoma exemplifies personalised decision-making in complex multidisciplinary care, where transparency about what is known, what is uncertain, and where value judgements enter is preferable to further algorithmic refinement.
๐๐๐@Vaital73, Gordon Guyatt, Masatoshi Kudo, Laura Kulik, David J Pinato, Laura Crocetti, Edoardo G Giannini, @prof_cillo
#SoMe4Surgery #MedTwitter #SurgEd #Surgery @BJSAcademy@BJSurgery #HPBSurgery #LiverSurgery #HCC #SurgicalOncology #EvidenceBasedSurgery
Uncertainty in medicine isn't a flaw to engineer away with finer algorithms. It's intrinsic to every individual decision.
Our new paper in BJS Open traces 20 years of liver cancer to make the case. Honoured to have Gordon Guyatt as co-author.
https://t.co/fgsAwpluer
๐ Small p-NET <2cm always a challenge
๐ฎ๐น ๐ฏ๐ต ๐ซ๐ท ๐น๐ท ๐ฌ๐ง ๐ฉ๐ช 460 resected / 35% enucleation
โ ๏ธ Central panc morbidity 25% ๐ enucleation 10% and โฌ๏ธ POPF / LOS
๐ซ LN Mets 14% ๐
My take: less (no surgery) is MORE!
https://t.co/o4qt6EZMZW
Of surgical dogma and lemonade ๐ managing the drain left after pancreatoduodenectomy
โ๏ธ Beautiful commentary by @HalletJulie in @BjsOpen a pleasure to read!
โโโ
https://t.co/DN5pAeJb13
Honored to represent @EurPancClub at the 53 Japan Pancreas Society ๐ช๐บ๐ค๐ฏ๐ต in Fukuoka
โ STOP surveillance in IPMN was a hot topic ๐ฅ but controversial
๐ฐ Current policies not cost effective but concomitant PDAC is a big issue in long run โฆ more evidence needed!
What do we mean with "recurrence" of IPMN ๐ after surgery ?!
โ๏ธ word - โ๏ธ different scenario
๐ IPMN after resection of non-invasive are "de novo" in 50% cases
๐ฆ Recurrence of invasive IPMN was 42%, most systemic if ๐ node + and tubular type
https://t.co/IgxtRGW9hZ
๐ฎ๐น LITALHICA proposes a new approach to LT for unresectable #PerihilarCCA: replacing Mayo chemoradiotherapy with modern systemic therapy for biological selection. A promising step in #TransplantOncology. ๐
https://t.co/cwjloCVUx4